Passage Bio

Founded 2017 · CIK 0001787297 · Biotech · Public

Gene therapies for severe monogenic CNS disorders

passagebio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$110M
1 Form D · Sep 2019
85 months since last filing
Contracts
—
No federal contracts on record
Patents
10
0 granted · 10 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$109,999,974
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2817LYST THERAPEUTICS LLC——
2818Relation Therapeutics—$116M
2819STEL Technologies, LLC——
2820Passage Bio—$110M
2821Acadia Pharmaceuticals—$107M
2822Neurogene Inc.—$106M
2823Ovid Therapeutics—$106M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 6 related persons
  • Carl GordonDirector
  • Patrick HeronDirector
  • Saqib IslamDirector
  • Stephen SquintoDirector · Executive Officer
  • Thomas Street Address 1 WoiwodeDirector
  • Tadataka YamadaDirector · Executive Officer · Promoter

Patents

USPTO · 0 granted of 10
  • Method Of Purifying Full Recombinant Aav Particlesapplication
  • Recombinant Adeno-associated Virus For Treatment Of Neurodegenerative Disordersapplication
  • Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
  • Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
  • Recombinant Adeno-Associated Virus for Treatment of Neurodegenerative Disordersapplication
  • Potency Assay Of Progranulinapplication
  • Recombinant Adeno-associated Virus For Treatment Of Neurodegenerative Disordersapplication
  • Method Of Purifying Full Recombinant Aav Particlesapplication
  • Potency Assay Of Progranulinapplication
  • Method Of Purifying Full Recombinant Aav Particlesapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.